Correvio Pharma Corp. announced the presentation of results from the SPECTRUM study evaluating Brinavess (vernakalant hydrochloride, IV), the Company's antiarrhythmic drug for the rapid conversion of recent onset atrial fibrillation (AF), at the European Society of Cardiology (ESC) 2019 Congress taking place August 31 ­ September 4, 2019, in Paris, France. SPECTRUM was conducted as part of the follow-up measures agreed to with the European Medicines Agency in 2010. In this prospective and retrospective, international, multicenter, observational registry, 1,778 unique patients with 2,009 treatment episodes were enrolled to describe patients receiving Brinavess and to characterize normal conditions of use and dosing, and quantify possible medically significant risks associated with the use of Brinavess in real-world clinical practice. The data for SPECTRUM was provided by 53 participating hospitals in the EU and demonstrated that treatment with Brinavess successfully converted 70.2% (95% confidence interval [CI] 68.1 ­ 72.2) of all treated episodes. Treatment with Brinavess also showed a median time to conversion of 12 minutes from start of first infusion among patients who converted. Cardioversion to sinus rhythm was 70.4% and 65.4% of treatment episodes in non-surgery and post-cardiac surgery patients, respectively. Brinavess was administered in the emergency department in 64.2% of cases, with a median stay of 7.5 hours in that setting. In the safety results, a total of 19 health outcomes of interest were reported in 17 of the 1778 patients enrolled (<1%). The cumulative incidence of HOIs at study completion was 0.8% (95% CI: 0.5%-1.4%). Twenty-eight serious adverse events (SAEs, including the 19 HOIs) were reported for 26 patients and no cases of torsades de pointes, ventricular fibrillation or deaths were reported in the study.